Αποτελέσματα Αναζήτησης
25 Ιαν 2023 · For all participants 12 years of age or older, vaccine effectiveness against severe infection resulting in hospitalization over days 15 to 99 after receipt of one monovalent booster dose was...
16 Σεπ 2022 · A total of 437 participants received a second booster dose of mRNA-1273.214; 3 participants had discontinued the study before they received the second booster and were excluded from all...
12 Απρ 2023 · In a trial of two bivalent Covid-19 boosters, effectiveness against severe infection resulting in hospitalization or death reached a level of 67.4% after 2 weeks and decreased to 38.4% after 20...
11 Μαΐ 2023 · This updated 5-year analysis of the pivotal cohorts in phase 2 of ZUMA-1 demonstrates continued durability of response and long-term survival in patients with refractory LBCL, with no new safety signals. At 5 years, estimated OS was 43% among all patients who had received treatment and 64% among those achieving a CR.
13 Απρ 2023 · Our findings suggest that, in adults aged 65 years or older, the vaccine effectiveness of the bivalent mRNA vaccine booester dose is 72% (95% CI 60–81) for COVID-19 related hospitalisation and 68% (42–82) for COVID-19-related death. Implications of all the available evidence.
29 Δεκ 2022 · The objectives phase 2/3 clinical trial aimed to assess the safety, reactogenicity, and immunogenicity of bivalent vaccine mRNA-1273.214 with monovalent mRNA-1273 28 days after their second booster dose.
ZUMA-23 is the first Phase 3, randomized controlled study to evaluate CAR T-cell therapy as a 1L regimen for any cancer and will assess axi-cel versus SOC in pts with high-risk LBCL, defined as IPI 4-5.
